Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase…

By Caicun Zhou, Yi-long Wu, Gongyan Chen, Jifeng Feng, Xiao‐qing Liu, Chang-li Wang, Shucai Zhang, Jie Wang, Songwen Zhou, S. Ren and 13 more. The Lancet Oncology, 2011

4,031 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/517e55b664d39653767b6f93afc0c385952c6fb1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Jie Yang
2. S. Rosenberg

In Pulmonary and Respiratory Medicine

1. B. Hughes
2. B. Chan
3. L. Sequist

Citations in the corpus

• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2016, background): “Rash incidence was higher with erlotinib, although only small numbers of participants experienced grade 3 to 4 rash.(13) In both studies of selected patients, incidence of neutropenia, thrombocytopenia, and anemia was higher with chemotherapy.”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, background): “26) 12% less serious adverse events 4 [75]”
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. (2013, background): “Several previous phase III studies included only common sensitizing EGFR mutations (L858R and exon 19 deletions).(3,5,6) In our study, the preplanned analysis of those with common EGFR mutations (n 308) showed the magnitude of PFS benefit was even larger, with a median PFS (by independent review) of”
• Lung cancer: Biology and treatment options. (2015, background): “Three large controlled and randomized trials showed that gefitinib or erlotinib are better than platinum combination chemotherapy as first-line treatment for stage IIIB or IV lung adenocarcinomas in nonsmokers or former light smokers in East Asia [35,36,96,97].. Data from these trials demonstrated t”
• Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer (2018, background): “No mutation detected, invalid test, or no or inadequate sample 24 (9) 32 (12) Table 1.”